Navigation Links
New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
Date:11/7/2011

nt fever, bruising, bleeding, pallor) while on CIMZIA. Consider discontinuation of CIMZIA therapy in patients with confirmed significant hematologic abnormalities.

Drug Interactions

An increased risk of serious infections has been seen in clinical trials of other TNF blocking agents used in combination with anakinra or abatacept.  Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also result from the use of CIMZIA in these combinations.  Therefore, the combination of CIMZIA with anakinra, abatcept, rituximab, or natalizumab is not recommended.  Interference with certain coagulation assays has been detected in patients treated with CIMZIA. There is no evidence that CIMZIA therapy has an effect on in vivo coagulation. CIMZIA may cause erroneously elevated aPTT assay results in patients without coagulation abnormalities.

Autoimmunity

Treatment with CIMZIA may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. Discontinue treatment if symptoms of lupus-like syndrome develop.

Immunizations

Do not administer live vaccines or attenuated vaccines concurrently with CIMZIA.

Adverse Reactions

In controlled Crohn's clinical trials, the most common adverse events that occurred in greater than or equal to 5% of CIMZIA patients (n=620) and more frequently than with placebo (n=614) were upper respiratory infection (20% CIMZIA, 13% placebo), urinary tract infection (7% CIMZIA, 6% placebo), and arthralgia (6% CIMZIA, 4% placebo). The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 8% for CIMZIA and 7% for placeb
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research ... announced the addition of the "Investment Analysis ... report to their offering. ... investments in the US medical device sector identifies ... equity and venture capital investments, and mergers and ...
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a ... of epilepsy, today announced it will participate in the 33 ... 14, 2015, in San Francisco . ... Officer, will speak at 11:00 AM Pacific Time.  A live ... on the Investor Relations link on the Cyberonics home page ...
(Date:12/22/2014)... 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... following open letter to shareholders from President & ... Dear RXi Shareholders, In ... statements posted on certain social media sites seem ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... , June 21 Ethicon Endo-Surgery, Inc. ... line of surgical devices, the HARMONIC ACE® 45 cm ... the reach of surgeons for minimally invasive procedures involving ... the standard length HARMONIC ACE® device. The additional length ...
... 21 Pfizer Inc. (NYSE: PFE ) announced today ... it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) ... the United States and that it will be voluntarily withdrawing the ... , , , ...
Cached Medicine Technology:Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 2Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 2Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 4Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 5Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 6
(Date:12/26/2014)... It is said that nothing makes a lady feel ... wedding dress supplier, shows its new selection of navy ... , UWDress.com’s navy cocktail gowns are the cornerstones of ... fashion styles. Simple dresses in bright neon colors can be ... specially designed for those who want to shine among the ...
(Date:12/26/2014)... December 26, 2014 The Biofeedback Federation ... March 24-28, 2015 in Rome, Italy and is hosted ... workshops on a wide variety of topics ... as peak performance training in athletes. The scientific program ... world. , Biofeedback monitoring allows clients to see what ...
(Date:12/26/2014)... India Network Foundation, a non-profit US based ... today a new version of “ EasySelect ”, a ... plan for their visiting parents. The technology tool is ... process when choosing an insurance plan by showing the ... few clicks. Many elderly Asian Indian parents often find ...
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... The click strand woven bamboo ... durability. Today, the business announces a click strand ... Jan. 30, 2015. , Click strand woven bamboo ... is a well-known brand in the bamboo industry. ... a reliable bamboo flooring supplier. , “We are ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2
... Haglund’s syndrome, a common running ailment, can be treated in ... Adler, chief, Division of Ultrasound// and Body CT, the ultrasound ... relieve the pain of the patient. ,One condition ... painful bump on the back of the heel, caused by ...
... (AU) and the UN system in Africa on Tuesday launched ... Region//. Aids prevention matters were the top priority at the ... The programme aims to curb the spread on the pandemic, ... Oumar Konare said at a launching ceremony, held at the ...
... than 1lb 6oz. He was so weak that he needed life ... he lived and grew stronger. //Even his mother Donna Morgan who ... be given blood transfusions to recover. ,Now the mother ... helped them, they are launching a campaign to fill the worryingly ...
... lithotripsy, which is given for treating kidney stones have increased ... of life. //Risk for diabetes was related to the intensity ... hypertension was related to treatment of stones in both kidneys. ... up an impassable kidney stone into smaller, sandlike pieces which ...
... said that suicide rates in Sri Lanka has increased in multifold ... oleander plants even for the most trivial reasons. ,This ... over the island. It has yellow trumpet-like flowers and a fruit ... and one of these seeds is enough to kill you, the ...
... Health Minister Ashok Bhatt has confirmed the absence of bird-flu ... bird-flu// also yielded negative results. ,Kadar Murghiwala, a ... his care died. Suspecting a possible bird-flu infection following complaints ... kept in an isolation ward. The symptoms of bird-flu as ...
Cached Medicine News:Health News:Proper Diagnosis Could Augment Speedy Recovery Of Haglund’s Syndrom 2Health News:African Union Launches A Programme On Acceleration of HIV Prevention 2Health News:Shock Wave Therapy Increase The Risk Of Diabetes 2Health News:Shock Wave Therapy Increase The Risk Of Diabetes 3
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,407-0) or contact custom...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... is the #1 Pipettor for sub-microliter ... and reliability. Continuously adjustable. Features lPLUS, ... Easy interchangeable ejector buttons to fit ... rapid pipet tip ejector with three ...
... digital models cover the range from 2ul to ... Volume lock design prevents inadvertent volume change. ... grip. Whole pipette is autoclavable at 121C(250F). ... all polypropylene. Suitable for one-handed operation. ...
Medicine Products: